Business Context and Reporting Period
This Form 8-K reports on the results of the 2019 Annual Meeting of Stockholders held by Capricor Therapeutics, Inc. on May 29, 2019. The meeting was conducted at the company's principal executive offices in Beverly Hills, California.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Stockholders representing 28,119,643 of the 34,515,815 shares entitled to vote participated in the meeting. The following proposals were approved:
- Director Elections: All six nominees (Frank Litvack, Linda Marbán, David B. Musket, George W. Dunbar, Jr., Louis Manzo, and Earl M. (Duke) Collier, Jr.) were elected to the Board of Directors. Significant broker non-votes (approx. 13.5 million shares) were recorded for these proposals.
- Auditor Ratification: The appointment of Rose, Snyder & Jacobs LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified with 27,075,425 votes in favor.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-3 and 1-for-15. The specific ratio and timing are at the sole discretion of the Board of Directors. This proposal received 23,580,473 votes in favor.
- Adjournment Authority: The meeting was authorized to adjourn if necessary to solicit additional proxies for the reverse stock split proposal.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific operational risks. The primary contingency noted is the Board's discretion to determine the specific ratio and timing of the authorized reverse stock split.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once determined by the Board of Directors.
- Review the definitive proxy statement filed on April 30, 2019, for detailed biographies of the newly elected directors.
- Monitor future filings for the implementation of the reverse stock split and its impact on share count and trading price.
- Confirm the company's financial status in subsequent periodic reports (10-Q or 10-K) as this 8-K contains no financial data.